Items Tagged ‘mpn’

December 20th, 2016

5-Year Survival Improved with Early Use of Jakafi® in Myelofibrosis

By

An analysis of 5-year data from two large clinical trials provide conclusive support that treatment with Jakafi® (ruxolitinib) improves long-term survival, compared to other treatment options for patients with myelofibrosis. Perhaps even more importantly, the data suggests that treatment with Jakafi should be used much earlier in the course of a patient’s disease because it […]

View full entry

Tags: 2016, Acute Myeloid Leukemia, American Society of Hematology, ASH, COMFORT-I, COMFORT-II, essential thrombocythemia, jakafi, MF, mpn, myelofibrosis, myeloproliferative neoplasm


December 16th, 2016

Interferon No Better Than Hydroxyurea and Associated with Worse Side Effects in Polycythemia Vera and Essential Thrombocythemia

By

The use of interferon as initial therapy in MPN is associated with worsening side effects the longer it is used for treatment. These results were recently presented at the 2016 annual meeting of the American Society of Hematology. Myeloproliferative neoplasms (MPNs) are a related group of blood cancers. In these disorders, the bone marrow cells […]

View full entry

Tags: 2016, American Society of Hematology, ASH, essential thrombocythemia, ET, hydroxyurea, Interferon, interferon alpha-2a, MPD-RC 112 trial, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN


October 10th, 2016

Myeloproliferative Neoplasms Greatly Affect Patient Quality of Life

By

According to results from the myeloproliferative neoplasms (MPN) Landmark survey, MPN’s negatively affect the quality of life and overall health of patients even a year before their diagnosis. Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three […]

View full entry

Tags: essential thrombocythemia, ET, mpn, Myeloproliferative Neoplasms MPN, News, PMF, polycythemia vera, primary myelofibrosis, PV


June 21st, 2016

Jakafi Superior to Standard Treatment in Polycythemia Vera

By

Treatment with Jakafi® (ruxolitinib) was superior to best available treatment among patients with inadequately controlled polycythemia vera (PV). These results were recently presented at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. PV is a type of myeloproliferative neoplasm (MPN) in which the body produces a larger than normal amount of […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


April 27th, 2016

Pacritinib Development in Myelofibrosis Placed on Clinical Hold by the FDA

By

The investigative agent, pacritinib, being evaluated for treatment of myelofibrosis has been placed on full clinical hold by the United States Food and Drug Administration (FDA). All trials including treatment involving pacritinib have been stopped, and the New Drug Application (NDA) to the FDA for pacritinib has been withdrawn.1 Myelofibrosis is a type of blood […]

View full entry

Tags: clinical hold, fda, mpn, myelofibrosis, myeloproliferative neoplasm, Myeloproliferative Neoplasms MPN, NDA, News, pacritinib, withdrawn


February 10th, 2016

Year in Review: Myeloproliferative Neoplasms

By

Individuals dealing with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis, typically experience difficult symptoms, life-threatening complications, and are at risk of progression to acute leukemia. The development and approval of the JAK2 inhibitor Jakafi® (Ruxolitinib) has led to more effective management of these symptoms in many patients with PV, positively […]

View full entry

Tags: essential thrombocythemia, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, research, review


April 21st, 2015

What you Need to Know about Itching and Myeloproliferative Neoplasms

By

What you Need to Know about Itching and Myeloproliferative Neoplasms If you have been diagnosed with myelofibrosis or polycythemia vera, you may have experienced itching as a side effect. Itching occurs as a result of the activity of cytokines (small proteins involved in cell signaling) associated with myeloproliferative neoplasms (MPNs) and because a certain type […]

View full entry

Tags: itching, jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, ruxolutinib


April 14th, 2015

Jakafi® Provides Important Symptom Relief in Patients with Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these […]

View full entry

Tags: blood cancer, hydrea, hydroxyurea, improvement, jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


March 25th, 2015

Pacritinib May Be Effective against Myelofibrosis without Risk of Myelosuppression

By

The investigational agent pacritinib appears active against myelofibrosis without the risk of myelosuppression, a common side effect of many drugs used to treat myelofibrosis and other myeloproliferative neoplasms (MPN). The developers of pacritinib, CTI BioPharma Corp and Baxter International Inc, announced these findings from a Phase III clinical trial called PERSIST-1. Myelofibrosis is a type […]

View full entry

Tags: blood cancer, mpn, myelofibrosis, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, pacritinib, PERSIST-1, research


February 17th, 2015

Phase III Trial Finds Jakafi Superior to Standard Therapy for Polycythemia Vera

By

A Phase III trial finds that Jakafi® (ruxolitinib) is more effective than standard therapy for patients with polycythemia vera (PV). These findings were published in the New England Journal of Medicine. Polycythemia vera is a slow-growing type of blood cancer that belongs to a group of blood disorders called myeloproliferative neoplasms (MPN). In these disorders, […]

View full entry

Tags: hydrea, hydroxyurea, jak1, JAK2, jakafi, mpn, Myeloproliferative Neoplasms MPN, myeloproliferative neoplastms, News, polycythemia vera, PV, PV treatment


January 22nd, 2015

Myeloproliferative Neoplasms: Making Progress in Polycythemia Vera and Myelofibrosis

By

Myeloproliferative neoplasms (MPN) are a related group of blood cancers. In these disorders, the bone marrow cells that produce blood cells develop and function abnormally. The three main types of MPN are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). In addition to developing on its own, myelofibrosis may also develop as a […]

View full entry

Tags: jakafi, mpn, myelofibrosis, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV


December 16th, 2014

Jakafi® Helps Maintain Blood Cells Levels in Polycythemia Vera

By

CancerConnect News: A new drug called Jakafi® (ruxolitinib) appears to help patients with polycythemia vera (PV) maintain hematocrit control more effectively than best available therapy. These findings were presented at the 56th American Hematology Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California.[1] Polycythemia vera is a slow-growing type of blood cancer […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV, ruxolitinib


December 15th, 2014

Switching from Best Available Therapy to Jakafi® Improves Outcomes in Polycythemia Vera

By

Patients with polycythemia vera (PV) who begin treatment with best available therapy and then switch to treatment with Jakafi® (ruxolitinib) experience improved outcomes. These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Polycythemia vera is a slow-growing type of blood cancer that belongs […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, polycythemia vera, PV


December 11th, 2014

Jakafi® Appears Effective in the Treatment of Essential Thrombocythemia

By

By interfering with protein signaling linked to blood cell production, Jakafi® (ruxolitinib) may be effective in the treatment of essential thrombocythemia (ET) in patients who progress on or can’t tolerate Hydrea® (hydroxyurea). These findings were presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Essential thrombocythemia […]

View full entry

Tags: jakafi, mpn, myeloproliferative neoplasms, Myeloproliferative Neoplasms MPN, News, ruxolitinib


December 5th, 2014

Jakafi: First Drug Approved for Treatment of Polycythemia Vera

By

The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition. Polycythemia vera occurs when too many red blood cells are made in the bone marrow. Patients […]

View full entry

Tags: jakafi, mpn, Myeloproliferative Neoplasms MPN, News, PV